Hormone therapy and radiotherapy for intermediate risk prostate cancer.
The optimal therapy for prostate cancer classified as "intermediate risk" on the basis of prostate-specific antigen, Gleason score, and clinical T stage is currently evolving. The role of hormonal therapy in these patients remains controversial, particularly in the setting of dose-escalated radiation. In this review, we examine the currently available data and describe maturing studies that address the optimal timing, duration, and potential risks and benefits of adding hormonal therapy to external-beam radiation for intermediate-risk patients. We conclude that until additional data become available, a short course of androgen deprivation, concurrent with radiation, should be considered in selected intermediate-risk patients who may be at greatest risk for failure if treated with external-beam radiation alone.
Lee
Irwin
I
Department of Radiation Oncology, University of Michigan, 1500 Medical Center Drive, Ann Arbor, MI, USA.
Sandler
Howard
H
D000726:Androgen Antagonists / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D011879:Radiotherapy Dosage; D013997:Time Factors
D000726:Androgen Antagonists